A trusted partner for DNA synthesis
Emeryville, Calif.BiotechFounded 2018
21 sources · checked 1 time, last 1d ago
3 sources
The source reports $45.2 million closed plus commitments for an additional $9.2 million; the latter is not counted as closed round money. The article is dated October 9, while the embedded release identifies the announcement as October 1.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $71.5M $211M to date | 2026-11-18 | Blue Water Life Science Advisors | 1 person on X · 15 outlets. #21 in Trending |
21 sources · checked 1 time, last 1d ago [ VERIFIED · CORRECTED ] read against 1 of 21 sources
[ BUILT WITH ]·[ SEARCH ]found on a watched publisher·[ SCRAPE ]21 pages read: businesswire.com, venturebeat.com, biospace.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 21 sources·[ ]posts from 1 person, found with Firecrawl search·[ AGENT ]company research by the Firecrawl agent | ||||
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $54.4M | 2025-10-01 | Cerberus Ventures | No recent discussion |
3 sources [ VERIFIED · CORRECTED ] read against 1 of 3 sources
The source reports $45.2 million closed plus commitments for an additional $9.2 million; the latter is not counted as closed round money. The article is dated October 9, while the embedded release identifies the announcement as October 1. | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A | $68 million | 2022-04-11 | Northpond Ventures | |
1 person on 15 outlets
Found on X with Firecrawl search
Ansa Biotechnologies makes long, complex synthetic DNA for researchers and biotechnology, pharmaceutical, and other biology teams using an enzymatic synthesis platform.
Conventional chemical synthesis struggles with long, complex sequences, delaying or forcing redesign of experiments; Ansa’s enzymatic platform produces sequence-perfect clonal DNA up to 50 kb and sequence-verified fragments, with a missed-ship-date-free guarantee. The $71.5 million Series C brings total funding to $211 million after the company quadrupled manufacturing capacity, signaling a bet that reliable access to difficult DNA can unlock AI-enabled drug discovery, cell and gene therapies, vaccines, and agrigenomics.
Checked against 13 sources yesterday
Also named as backers in company research: Fifty Years, Horizons Ventures, Mubadala Capital, Humboldt Fund, Northpond Ventures, RA Capital, Fiscus Ventures, PEAK6 Strategic Capital, Carbon Silicon Ventures, Codon Capital